sucujovide.wordpress.com
Lamictal, which treats epilepsy and bipolar disorder, was a blockbustert drug for GSK (NYSE: GSK) befores generic competition was introducexd inthe U.S. market last year. Worldwidwe sales of Lamictal were down 61 to $207 million, . Blockbuster drugs have annual sales of morethan $1 billion. England-basexd GSK, which bases its U.S. operation in Research Triangle Park. is touting its new version of Lamictall as a better option for epilepsy and bipolar patients that have troubled swallowingregular pills.
Milan, Italy-basex (Nasdaq: EURX) partnered with GSK in developing the disintegrating Lamical tablet and has a patentg pending on the new AGlaxoSmithKline spokeswoman, citing companu policy, declined to say how much the new versioj of Lamictal might generate in sales. The origina l version of Lamictal was developer more than a decade ago byBurroughas Wellcome, an RTP-based company that became GlaxoSmithKline after a seriee of mergers. GSK is one of the largest employers inthe Raleigh-Durha m area.
The company employs 4,000 people in RTP and abougt 1,000 more at a manufacturing facility in the easternm Wake County townof
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment